Bracco Diagnostics
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Bracco Diagnostics sits in the top decile of US sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count).
Bracco Diagnostics: 37 sponsored US clinical trials, 1 recruiting.
Bracco Diagnostics sponsors 37 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 29 completed. 20 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Renal Insufficiency, with 2 trials.
Top-decile sponsor footprint
Bracco Diagnostics ranks in the top decile of sponsors by registered trial count (#456 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
29 of 36 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
37 total, page 1 of 1
Lumason® Infusion vs. Bolus Administrations
NCT06400004
Study With Oral Isovue in Abdominopelvic CT
NCT04453059
Optimal Timing of BR55 CEUS of the Ovaries
NCT04248153
Thyroid Function of Pediatric Subjects Following Isovue® Administration
NCT03779906
BR55 in Characterization of Ovarian Lesions
NCT03493464
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
NCT03750188
Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions
NCT03486327
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
NCT03147989
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142
NCT02552238
Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography
NCT02282163
Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141
NCT02522481
Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control
NCT03108378
A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer
NCT02142608
Crossover Comparison of MultiHance and Dotarem
NCT02070380
Multidetector Computed Tomography (MDCT) Tailored Protocol
NCT01737333
Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
NCT01613417
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning at Two Clinical Sites
NCT01430975
Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning
NCT01424774
Safety of SonoVue on Pulmonary Hemodynamics
NCT01306292
Kidney Damage in Patients With Normal eGFR
NCT01137786
Kidney Damage in Patients With Moderate Fall in eGFR
NCT01136876
SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization
NCT00829413
Isovue in Peripheral Digital Subtraction Angiography (DSA)
NCT01075217
SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization
NCT00788697
Renal Safety of Iopamidol Versus Iodixanol During Coronary Angiography in Diabetic Patients
NCT00782639
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
NCT00773409
Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
NCT00600834
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
NCT00600951
Coronary MDCTA With Iopamidol Injection 370
NCT00558792
Follow-up Study to Previous CARE Trial
NCT00479024
Multihance at 3 Tesla (3T) in Brain Tumors
NCT00395863
Detection of Pulmonary Embolism With CECT
NCT00351754
A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain
NCT00323102
Safety and Efficacy of MultiHance in Pediatric Patients
NCT00323310
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
NCT00289614
A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
NCT00289029
Patients With Renal Impairment Undergoing CT
NCT00292487
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 7 |
| Phase 4 | 13 |
Where Bracco Diagnostics enrollment is open (later-stage tilt)
1 recruiting of 37 indexed (3% open); 29 completed (78%).
Phase mix: 20 late (III/IV) vs 6 early (I/II) (later-stage heavy).
Top condition: Renal Insufficiency (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bracco Diagnostics: open-pipeline peers nationwide
Peers matched on 37 registered trials and 3% open enrollment, not the therapeutic-area sidebar.
Bracco Diagnostics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 37 trials (± recruiting share)
- Appalachian State University · 37 trials · 3% recruiting
- Carnegie Mellon University · 37 trials · 11% recruiting
- Cutera · 37 trials · 0% recruiting
- Harvard University · 37 trials · 5% recruiting
Sponsors near 3% open enrollment (± trial volume)
- Janssen Scientific Affairs · 3% recruiting · 37 trials
- Nektar Therapeutics · 3% recruiting · 37 trials
- Enanta Pharmaceuticals · 3% recruiting · 36 trials
- Eastern Cooperative Oncology Group · 3% recruiting · 141 trials
Related
What to do with this Bracco Diagnostics page
37 registered trials is a research-attention snapshot, not an endorsement of Bracco Diagnostics or any single study.
- 1 of Bracco Diagnostics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Renal Insufficiency is the condition Bracco Diagnostics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Renal Insufficiency trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bracco Diagnostics pipeline card: 37 registered trials from official public datasets.Report a data error.